THE HEALTH IMPACT OF PEMBROLIZUMAB AS FIRST-LINE (1L) TREATMENT FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) IN TURKIYE
Author(s)
Burcu Akyol Ersoy, BSc, MBA1, Nuri Karadurmus, Prof. Dr.2, Ugur Akpamuk1, Yasemin Ceylan1, Gozde Ozcan, MSc1, Yasemin Esen, MD1, Mert Batum, MD1, Berfin Torun, MD1, Bernadette Poellinger, PhD3, Carole Mamane, BSc, MSc4, Rebekah Heinzen Borse, PhD5, Adnan Alsumali, PhD6, Maulidia Ekaputri, MD7, Mehmet Ali Nahit Sendur, Prof. Dr.8, Sercan Aksoy, Prof. Dr.9.
1Merck Sharp & Dohme Ltd. (Turkey), Istanbul, Turkey, 2Gulhane Training and Research Hospital, Ankara, Turkey, 3MSD Sharp & Dohme GmbH, München, Germany, 4MSD France, Puteaux, France, 5Merck Sharp & Dohme LLC, Rahway, NJ, USA, 6Merck Sharp & Dohme IDEA Middle East, Dubai, United Arab Emirates, 7Amaris Consulting, Paris, France, 8Yıldırım Beyazıt University Medical Faculty, Ankara, Turkey, 9Hacettepe University Faculty of Medicine, Ankara, Turkey.
1Merck Sharp & Dohme Ltd. (Turkey), Istanbul, Turkey, 2Gulhane Training and Research Hospital, Ankara, Turkey, 3MSD Sharp & Dohme GmbH, München, Germany, 4MSD France, Puteaux, France, 5Merck Sharp & Dohme LLC, Rahway, NJ, USA, 6Merck Sharp & Dohme IDEA Middle East, Dubai, United Arab Emirates, 7Amaris Consulting, Paris, France, 8Yıldırım Beyazıt University Medical Faculty, Ankara, Turkey, 9Hacettepe University Faculty of Medicine, Ankara, Turkey.
OBJECTIVES: A global incidence of 947,211 cases of head and neck cancer was estimated in 2022. In Türkiye, head and neck cancer accounted for 8,144 new cases and 3,084 deaths in the same year.
This analysis aims to evaluate the health impact of pembrolizumab either as monotherapy or in combination therapy compared to cetuximab+platinum+5-FU (EXTREME regimen) as first line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) in the PD-L1 CPS≥ 1 patient population.
METHODS: A three-state partitioned survival model was adapted to the Turkish payer perspective to assess the health impact of pembrolizumab in terms of life years (LYs) and quality-adjusted life years (QALYs) over a lifetime horizon with 3% annual discounting. Efficacy, safety and utility data were based on the KEYNOTE-048 trial (data cut-off February, 2022). Deterministic (DSA) and probabilistic sensitivity analyses (PSA) were conducted to test the robustness of the model results.
RESULTS: Pembrolizumab monotherapy increased effectiveness per patient by 0.91 LYs (from 1.54 to 2.45) and 0.65 QALYs (from 1.12 to 1.77) compared with the EXTREME regimen. Pembrolizumab combination therapy increased per patient LYs by 0.56 (from 1.54 to 2.09), and QALYs by 0.40 (from 1.12 to 1.52) in comparison with the EXTREME regimen. Results from the DSA and PSA support the robustness of base-case results and the overall model conclusions did not change across the sensitivity analyses.
CONCLUSIONS: The results indicate that, pembrolizumab both as monotherapy and combination therapy yields better outcomes in LYs and QALYs than the EXTREME regimen for patients with R/M HNSCC receiving 1L treatment in the PD-L1 CPS ≥1 population in Türkiye.
This analysis aims to evaluate the health impact of pembrolizumab either as monotherapy or in combination therapy compared to cetuximab+platinum+5-FU (EXTREME regimen) as first line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) in the PD-L1 CPS≥ 1 patient population.
METHODS: A three-state partitioned survival model was adapted to the Turkish payer perspective to assess the health impact of pembrolizumab in terms of life years (LYs) and quality-adjusted life years (QALYs) over a lifetime horizon with 3% annual discounting. Efficacy, safety and utility data were based on the KEYNOTE-048 trial (data cut-off February, 2022). Deterministic (DSA) and probabilistic sensitivity analyses (PSA) were conducted to test the robustness of the model results.
RESULTS: Pembrolizumab monotherapy increased effectiveness per patient by 0.91 LYs (from 1.54 to 2.45) and 0.65 QALYs (from 1.12 to 1.77) compared with the EXTREME regimen. Pembrolizumab combination therapy increased per patient LYs by 0.56 (from 1.54 to 2.09), and QALYs by 0.40 (from 1.12 to 1.52) in comparison with the EXTREME regimen. Results from the DSA and PSA support the robustness of base-case results and the overall model conclusions did not change across the sensitivity analyses.
CONCLUSIONS: The results indicate that, pembrolizumab both as monotherapy and combination therapy yields better outcomes in LYs and QALYs than the EXTREME regimen for patients with R/M HNSCC receiving 1L treatment in the PD-L1 CPS ≥1 population in Türkiye.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO19
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
Oncology